# Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Study · id `cardio:ct-nct04481919` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04481919](<https://clinicaltrials.gov/study/NCT04481919>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04481919

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 474 participants.

## Technical summary

Registry record NCT04481919. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-01 (actual); primary completion 2025-11-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 474 participants (planned count; ClinicalTrials.gov record NCT04481919, source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)
- Started: 2022-05-01 (actual) (ClinicalTrials.gov record NCT04481919, source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)
- Primary completion: 2025-11-22 (actual) (ClinicalTrials.gov record NCT04481919, source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)
- Completion: 2027-02-28 (anticipated) (ClinicalTrials.gov record NCT04481919, source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT04481919, source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04481919-2026-09-21`, retrieved 2026-11-18)

## The registry's words

- Brief title: Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)
- Acronym: ESCALATE
- Condition: Heart Failure
- Condition: Acute Heart Failure
- Intervention (Drug): Protocolized diuretic therapy
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)

## Provenance

Content hash: 52d05271d7e6ede16721d195e2e202025c5f09073dc4defab51a78713465ae45
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
